Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.
| Condition(s) | Alzheimer Disease |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics. |
| Who can participate | Inclusion Criteria: 1. Age 50-90, inclusive 2. Diagnosis: Mild Cognitive Impairment (MCI) or mild AD dementia with positive cerebrospinal fluid (CSF) or amyloid PET 3. Objective measurement of baseline cognition and function within past 3 months: * Cognitive: Mini-Mental State Examination (MMSE) ≥ 22, MoCA ≥ 16 * Function: Independence in basic ADLs * Function: FAQ ≤ 9 may justify inclusion with lower cognitive score if felt to be impacted by prominent language impairment or other factors affecting score 4. MRI brain within last year and no exclusionary criteria 5. Complete blood count (CBC), comprehensive metabolic panel (CMP), B12, thyroid stimulating hormone (TSH), prothrombin time (PT), partial thromboplastin time (PTT), and International Normalized Ratio (INR) without clinically signi |
| Ages | 50 Years to 90 Years |
| Sex | All |
| Lead sponsor | Emory University |
| Locations | Albany, Georgia, United States; Atlanta, Georgia, United States; Atlanta, Georgia, United States; Augusta, Georgia, United States; Gainesville, Georgia, United States; Macon, Georgia, United States (+2 more sites) |
| Start date | 2025-03-06 |
| NCT ID | NCT05999084 |
| Official listing | https://clinicaltrials.gov/study/NCT05999084 |